All News
Filter News
Found 210 articles
-
Reverie Labs Raises $25M Series A Round to Broaden Impact of its Computational Kinase Drug Discovery Platform
2/3/2021
Reverie Labs, a pharmaceutical company pioneering the application of machine learning to developing next-generation small molecule kinase inhibitors, today announced the closure of its $25M Series A financing, and the addition of Wayne Holman, M.D., founder and CEO of Ridgeback Capital, to Reverie's Board of Directors
-
Clinical Catch-Up: January 25-29
2/1/2021
It was a busy week for clinical trial news. Read on for more information. -
Merck announced that it is going to stop developing its two COVID-19 vaccine candidates, dubbed V590 and V591, after poor responses in Phase I trials.
-
Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates
1/25/2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110.
-
Backed by Leaps by Bayer, Bay Area-based Senti Biosciences secured $105 million in a Series B financing round that will help the company advance its therapeutic pipeline of allogeneic chimeric antigen receptor natural killer (CAR-NK) cell therapies.
-
Leaps by Bayer Leads USD 105 Million Series B Financing in Senti Bio to Develop Next-Generation Cell and Gene Therapies Using Advanced Gene Circuit Technology Platform
1/6/2021
Leaps by Bayer and Senti Biosciences, Inc., a leading gene circuit company, today announced a USD 105 million Series B financing round.
-
In the first week of the new year, two companies raised more than $150 million in separate Series A financing rounds to fund research programs aimed at developing treatments for cancer and rare diseases.
-
Aro Biotherapeutics Announces $88 Million Series A Financing to Advance Development of Centyrin-Targeted Genetic Medicines
1/5/2021
Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced the closing of an $88 million Series A financing.
-
Novus Therapeutics Announces Name Change to Eledon Pharmaceuticals; Provides Corporate Update and Outlook
1/4/2021
Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons living with an autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today provided a corporate update and offered its outlook for 2021 and beyond.
-
Merck Announces Supply Agreement with U.S. Government for Initial Doses of Investigational Biological Therapy for the Treatment of Patients with Severe and Critical COVID-19
12/23/2020
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has entered into an agreement with the United States Government to support the development, manufacture and initial distribution of an investigational biological therapeutic (CD24Fc, to be named MK-7110) upon approval or Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Merck acquired MK-7110 through the acquisition of OncoImmune,
-
The U.S. Food and Drug Administration has approved several drugs and medical devices in the last week. Here’s a look.
-
Ridgeback Biotherapeutics LP Announces the Approval of EbangaTM for Ebola
12/22/2020
Ridgeback Biotherapeutics LP (“Ridgeback”), a biotechnology company experienced in antiviral drug development, announced today that the U.S. Food and Drug Administration (“FDA”) approved Ebanga TM for the treatment of Ebola. Ebanga is now approved for treatment of infection caused by Zaire ebolavirus in adult and pediatric patients (including neonates
-
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2020
12/15/2020
ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal year ended September 30, 2020.
-
Moderna’s stock has boomed over the course of 2020, and Merck is cashing in.
-
Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement
11/30/2020
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) and Viracta Therapeutics, Inc., a privately held precision oncology company targeting virus-associated malignancies, today announced they have entered into a definitive merger agreement (the “Merger Agreement”) pursuant to which Viracta will combine with Sunesis in an all-stock transaction (the “Merger”).
-
Merck acquired OncoImmune and its COVID-19 therapeutic candidate CD24Fc for $425 million in upfront cash two months after the Phase III asset demonstrated efficacy during an interim analysis.
-
Merck to Acquire OncoImmune
11/23/2020
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and OncoImmune, a privately-held, clinical-stage biopharmaceutical company, today announced that the companies have entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of OncoImmune for an upfront payment of $425 million in cash.
-
miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
11/10/2020
Recently completed acquisition of Viridian Therapeutics, including an anti-IGF-1R monoclonal antibody, VRDN-001, for the potential treatment of thyroid eye disease (TED) Private placement financing proceeds of approximately $91 million positions miRagen to potentially advance multiple compounds through Phase 2 proof of concept studies in TED and expand its orphan disease pipeline
-
miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.
10/28/2020
Acquisition includes clinicalstage anti-IGF-1R monoclonal antibody, VRDN-001, intended for the treatment of thyroid eye disease (TED)
-
Merck Announces Third-Quarter 2020 Financial Results
10/27/2020
Third-Quarter 2020 Worldwide Sales Were $12.6 Billion, an Increase of 1%; Excluding the Impact from Foreign Exchange, Sales Grew 2%